Agency Business briefs

Share this article:
Zeno Group named former Burson healthcare head Ame Wadler managing director for health and strategic planning. Wadler joins the firm from MWW Group, where she was EVP, chief management officer. Before that, she was chief strategic officer at Burson and chairman of the global healthcare practice.

Draftfcb named Peter Hudspeth and Jeff Daniels joint managing directors of Draftfcb Healthcare London. Both join the agency from LEC/TBWA/WorldHealth. Based in London, the pair will report to Draftfcb CEO and president Dana Maiman in New York.

Compass Healthcare Marketers is opening a satellite office in San Francisco. The specialty-focused, Princeton, NJ-based agency's Bay Area and Southern California clients include Actelion Pharmaceuticals, Baxter, Ipsen, Prometheus Therapeutics and Diagnostics, and Santarus, Inc.

Roska Healthcare Advertising named Ross Thomson chief creative officer. Thomson joins Roska from Vox Medica, where he was chief ideation officer, having presided over the shop's new brand identity.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?